Picking and Choosing Among Phase I Trials: A Qualitative Examination of How Healthy Volunteers Understand Study Risks
Journal of Bioethical Inquiry 16 (4):535-549 (2019)
AbstractThis article empirically examines how healthy volunteers evaluate and make sense of the risks of phase I clinical drug trials. This is an ethically important topic because healthy volunteers are exposed to risk but can gain no medical benefit from their trial participation. Based on in-depth qualitative interviews with 178 healthy volunteers enrolled in various clinical trials, we found that participants focus on myriad characteristics of clinical trials when assessing risk and making enrolment decisions. These factors include the short-term and long-term effects; required medical procedures; the type of trial, including its design, therapeutic area of investigation, and dosage of the drug; the amount of compensation; and trust in the research clinic. In making determinations about the study risks, participants rely on information provided during the consent process, their own and others’ experiences in clinical trials, and comparisons among studies. Our findings indicate that the informed consent process succeeds in communicating well about certain types of risk information while simultaneously creating lacunae that are problematically filled by participants through their collective experiences and assumptions about risk. We discuss the ethical implications of these findings and make recommendations for improving the consent process in healthy volunteer trials.
Similar books and articles
Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events.Lisa McManus, Arlene Davis, Rebecca L. Forcier & Jill A. Fisher - 2019 - Journal of Law, Medicine and Ethics 47 (2):323-333.
Healthy Volunteers for Clinical Trials in Resource-Poor Settings: National Registries Can Address Ethical and Safety Concerns.Francois Bompart - 2019 - Cambridge Quarterly of Healthcare Ethics 28 (1):134-143.
Volunteer experiences and perceptions of the informed consent process: Lessons from two HIV clinical trials in Uganda.Agnes Ssali, Fiona Poland & Janet Seeley - 2015 - BMC Medical Ethics 16 (1):1-14.
Phase 1 oncology trials and informed consent.Franklin G. Miller & Steven Joffe - 2013 - Journal of Medical Ethics 39 (12):761-764.
Serial Participation and the Ethics of Phase 1 Healthy Volunteer Research.Rebecca L. Walker, Marci D. Cottingham & Jill A. Fisher - 2018 - Journal of Medicine and Philosophy 43 (1):83-114.
Ethical Considerations for Volunteer Recruitment of Visual Prosthesis Trials.Yu Xia & Qiushi Ren - 2013 - Science and Engineering Ethics 19 (3):1099-1106.
The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials.Spencer Phillips Hey & Jonathan Kimmelman - 2014 - Kennedy Institute of Ethics Journal 24 (2):121-139.
Informed consent as an ethical requirement in clinical trials: an old, but still unresolved issue. An observational study to evaluate patient's informed consent comprehension.Virginia Sanchini, Michele Reni, Giliola Calori, Elisabetta Riva & Massimo Reichlin - 2014 - Journal of Medical Ethics 40 (4):269-275.
Are Phase 1 Trials Therapeutic? Risk, Ethics, and Division of Labor.James A. Anderson & Jonathan Kimmelman - 2014 - Bioethics 28 (3):138-146.
Newer Practice of Informed Consent Process of Clinical Trials in India.Barna Ganguly - 2016 - Asian Bioethics Review 8 (4):327-336.
Selected Issues Related to the Conduct, Reporting, and Analysis of Phase I Trials.Marcelle Denise Winget - 1996 - Dissertation, The Johns Hopkins University
Ethical reflections on clinical trials with human tissue engineered products.L. Trommelmans, J. Selling & K. Dierickx - 2008 - Journal of Medical Ethics 34 (9):e1-e1.
Deception in the Single-Blind Run-In Phase of Clinical Trials.Howard Mann - 2007 - IRB: Ethics & Human Research 29 (2).
Empty Ethics: The Problem with Informed Consent.Oonagh Corrigan - 2003 - Sociology of Health & Illness 25 (3):768-792.
An intervention to improve cancer patients' understanding of early-phase clinical trials.Nancy E. Kass, Jeremy Sugarman, Amy M. Medley, Linda A. Fogarty, Holly A. Taylor, Christopher K. Daugherty, Mark R. Emerson, Steven N. Goodman, Fay J. Hlubocky & Herbert I. Hurwitz - 2009 - IRB: Ethics & Human Research 31 (3):1.
Added to PP
Historical graph of downloads
Citations of this work
Promoting Ethical Payment in Human Infection Challenge Studies.Holly Fernandez Lynch, Thomas C. Darton, Jae Levy, Frank McCormick, Ubaka Ogbogu, Ruth O. Payne, Alvin E. Roth, Akilah Jefferson Shah, Thomas Smiley & Emily A. Largent - 2021 - American Journal of Bioethics 21 (3):11-31.
The ethical anatomy of payment for research participants.Joanna Różyńska - 2022 - Medicine, Health Care and Philosophy 25 (3):449-464.
References found in this work
Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials.Jill A. Fisher - 2015 - Science, Technology, and Human Values 40 (2):199-226.
Comprehension and Informed Consent: Assessing the Effect of a Short Consent Form.Leanne Stunkel, Meredith Benson, Louise McLellan, Ninet Sinaii, Gabriella Bedarida, Ezekiel Emanuel & Christine Grady - 2010 - IRB: Ethics & Human Research 32 (4):1.
Procedural misconceptions and informed consent: Insights from empirical research on the clinical trials industry.Jill A. Fisher - 2006 - Kennedy Institute of Ethics Journal 16 (3):251-268.
The promise of empirical research in the study of informed consent theory and practice.Laura A. Siminoff, Marie Caputo & Christopher Burant - 2004 - HEC Forum 16 (1):53-71.